Boston, Massachusetts, and Shenzhen, China, September 24, 2026
XtalPi has reached a significant milestone in its proprietary drug-development pipeline with the submission of a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application for KQTD-126, a potential first-in-class, gut-restricted pan-tropomyosin receptor kinase (pan-TRK) inhibitor. The investigational small-molecule candidate is being developed for chronic intestinal pain associated with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). The IND submission represents the first proprietary pipeline program from XtalPi to reach the clinical development application stage and marks an important step in the company’s transition toward a clinical-stage organization.
KQTD-126 Targets Chronic Intestinal Pain
KQTD-126 is designed to inhibit TRKA, TRKB and TRKC, members of the TRK receptor family that play important roles in nerve activity, pain signaling and sensory sensitization in the gastrointestinal tract. Chronic abdominal pain is a major symptom for many patients with IBS, while some individuals with IBD can continue experiencing pain even after treatment has controlled underlying inflammation. XtalPi is developing KQTD-126 to address this unmet need through localized inhibition of TRK signaling within the gastrointestinal tract. The company says IBS affects approximately 10%–15% of the global population, while more than 10 million people live with IBD. A key challenge in developing systemic TRK inhibitors is that TRK receptors are also present in the central nervous system. Systemic inhibition can therefore create concerns around neurological effects, particularly when a medicine is intended for long-term treatment. KQTD-126 has instead been designed to remain predominantly within the gut, with the objective of maintaining pharmacological activity at the disease site while limiting systemic exposure. This gut-restricted approach is central to the candidate’s proposed differentiation from conventional systemic TRK inhibitors.
Preclinical Data Support Gut-Restricted Activity
According to XtalPi, preclinical studies demonstrated sub-nanomolar pan-TRK inhibitory potency, with an ICâ‚…â‚€ below 1 nM, together with high selectivity against other kinases. The candidate also demonstrated a gut tissue-to-blood exposure ratio exceeding 1,000:1, supporting the company’s objective of concentrating drug exposure in gastrointestinal tissues while reducing circulating exposure. These findings remain preclinical and will need to be evaluated through human clinical studies following regulatory review of the IND application. The development of KQTD-126 also highlights XtalPi’s use of artificial intelligence and automated robotics in small-molecule drug discovery. The company describes a closed-loop process in which computational models guide molecular design, automated systems synthesize candidate compounds, experimental testing generates new data, and the resulting information is used for further molecular refinement. This approach was used to balance several challenging properties simultaneously, including target potency, kinase selectivity, tissue distribution and systemic exposure.
Advertisement
XtalPi Moves Proprietary Drug Program Toward Clinical Stage
The KQTD-126 IND filing represents an important development for XtalPi’s internal pipeline. The company has previously used its AI and robotics capabilities across multiple drug-discovery programs and partnerships, but KQTD-126 is the first proprietary program identified in its newly unveiled internal pipeline to reach the IND submission stage. If the FDA permits clinical development, XtalPi plans to evaluate the candidate’s safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy in clinical studies.
For cGxP.wire readers, the program is notable because it combines an emerging AI-driven drug-discovery platform with a specific therapeutic strategy for chronic gastrointestinal pain. Rather than attempting broad systemic TRK inhibition, KQTD-126 is being developed around the concept of localized gastrointestinal activity and reduced systemic exposure. The FDA IND submission does not establish clinical efficacy or safety, but it represents a regulatory milestone that could enable the candidate to progress from preclinical research into human testing.
Source: XtalPi press release
